PLIANT THERAPEUTICS, INC.
Business
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics. Its lead program PLN-101095 is an oral small molecule dual inhibitor of αvβ8 and αvβ1 integrins in development for solid tumors resistant to immune checkpoint inhibitors, having shown positive Phase 1 data in 2025. The company operates a proprietary drug discovery platform consisting of over 15,000 integrin binding molecules for potential development across immunology, inflammation, and oncology indications. Pliant discontinued bexotegrast development in idiopathic pulmonary fibrosis and primary sclerosing cholangitis following Phase 2 trial results.
Summary from 10-K filed 2026-03-11
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2 | 10 | 8 | |
| Research and development | −109 | −169 | −128 | −97 | −78 | |
| General and administrative | −47 | −59 | −58 | −40 | −28 | |
| Total operating expenses | −156 | −228 | −186 | −137 | −105 | |
| Loss from operations | −156 | −228 | −184 | −127 | −98 | |
| Interest and other income (expense), net | 11 | 21 | 24 | 5 | 272,000 | |
| Interest expense | −3 | −3 | −1 | −791,000 | — | |
| Loss on extinguishment of debt (Note 7) | −2 | 0 | — | — | — | |
| Net loss | −149 | −210 | −161 | −123 | −97 | |
| Net loss per share - basic (USD per share) | −2.43 | −3.47 | −2.75 | −2.94 | −2.71 | |
| Net loss per share - diluted (USD per share) | −2.43 | −3.47 | −2.75 | −2.94 | −2.71 | |
| Weighted average shares used in computing net loss per share - basic (in shares) | 61 | 61 | 59 | 42 | 36 | |
| Weighted average shares used in computing net loss per share - diluted (in shares) | 61 | 61 | 59 | 42 | 36 | |
| Net unrealized loss on short-term investments | −336,000 | −24,000 | 2 | −2 | −169,000 | |
| Total other comprehensive loss | −336,000 | −24,000 | 2 | −2 | −169,000 | |
| Comprehensive loss | −150 | −210 | −159 | −125 | −97 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 45 | 71 | 63 | 34 | 52 | |
| Short-term investments | 145 | 285 | 431 | 298 | 149 | |
| Prepaid expenses and other current assets (Note 5) | 4 | 7 | 11 | 7 | 7 | |
| Property and equipment held for sale (Note 4) | 1 | 0 | — | — | — | |
| Total current assets | 196 | 362 | 506 | 340 | 209 | |
| Property and equipment, net (Note 4) | 3 | 6 | 4 | 4 | 5 | |
| Operating lease right-of-use assets | 24 | 27 | 1 | 5 | 6 | |
| Restricted cash | 1 | 1 | 1 | 0 | — | |
| Other non-current assets | 392,000 | 435,000 | 392,000 | 394,000 | 838,000 | |
| Total assets | 225 | 397 | 512 | 351 | 221 | |
| Accounts payable | 480,000 | 6 | 5 | 2 | 3 | |
| Accrued research and development | 5 | 14 | 12 | 11 | 6 | |
| Accrued liabilities (Note 6) | 10 | 12 | 10 | 9 | 12 | |
| Lease liabilities, current | 1 | 542,000 | 1 | 2 | 2 | |
| Total current liabilities | 16 | 33 | 29 | 24 | 17 | |
| Lease liabilities, non-current | 28 | 29 | 0 | 3 | 5 | |
| Long-term debt (Note 7) | 0 | 30 | 10 | 10 | 0 | |
| Total liabilities | 44 | 93 | 39 | 37 | 22 | |
| Commitments and Contingencies (Note 14) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value 10,000,000 shares authorized at December 31, 2025 and 2024, none issued or outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | — | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2025 and 2024; and 61,449,290 and 60,860,838 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively; | 6,000 | 6,000 | 6,000 | 5,000 | 3,000 | |
| Additional paid-in capital | 1,041 | 1,014 | 973 | 654 | 414 | |
| Accumulated deficit | −859 | −710 | −500 | −338 | −215 | |
| Accumulated other comprehensive (loss) gain | −15,000 | 321,000 | 345,000 | −2 | −201,000 | |
| Total stockholders equity | 181 | 304 | 474 | 313 | 199 | |
| Total liabilities and stockholders equity | 225 | 397 | 512 | 351 | 221 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 2 | 2 | 2 | 2 | 2 | |
| Stock-based compensation expense | 26 | 38 | 44 | 23 | 10 | |
| Gain on sale of property plant and equipment | −44,000 | 0 | — | — | — | |
| Non-cash operating lease expense | 3 | 3 | 2 | 2 | 2 | |
| Amortization (accretion) on short-term investments | 4 | 3 | −5 | −2 | 1 | |
| Prepaid expenses and other current assets | 3 | 5 | −4 | −294,000 | −2 | |
| Other non-current assets | 43,000 | −43,000 | 0 | 201,000 | 70,000 | |
| Accounts payable | −5 | 1 | 3 | −1 | 891,000 | |
| Accrued liabilities | −12 | 4 | 3 | 8 | 3 | |
| Operating lease liabilities | −876,000 | −820,000 | −3 | −2 | −2 | |
| Net cash used in operating activities | −128 | −156 | −116 | −95 | −75 | |
| Purchase of short-term investments | −203 | −211 | −583 | −326 | −220 | |
| Maturity of short-term investments | 338 | 355 | 457 | 177 | 296 | |
| Purchase of property and equipment | −374,000 | −4 | −921,000 | −2 | −2 | |
| Proceeds from sale of property, plant and equipment | 155,000 | 0 | — | — | — | |
| Net cash provided by investing activities | 134 | 140 | −127 | −150 | 74 | |
| Proceeds from issuances of common stock under benefit plans | 570,000 | 3 | 5 | 1 | 3 | |
| Payment of debt | −32 | 0 | — | — | — | |
| Proceeds from term loan, net of issuance costs | 0 | 20 | 0 | 10 | 0 | |
| Net cash (used in) provided by financing activities | −32 | 23 | 274 | 227 | 3 | |
| Net (decrease) increase in cash and cash equivalents | −26 | 8 | 31 | −18 | 783,000 | |
| Cash paid for interest | 3 | 3 | 1 | 615,000 | 0 | |
| Purchase of property and equipment in accounts payable | 112,000 | 236,000 | 0 | 0 | 57,000 | |
| Cash paid for operating lease liabilities in operating cash flows | 6 | 5 | 4 | 3 | 2 | |
| Right-of-use assets obtained in exchange for new operating lease liabilities | 0 | 30 | 0 | 950,000 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is PLIANT THERAPEUTICS, INC.'s CIK number?
PLIANT THERAPEUTICS, INC.'s SEC CIK number is 0001746473 (1746473). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PLIANT THERAPEUTICS, INC.'s SEC filings?
All of PLIANT THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PLIANT THERAPEUTICS, INC. last report earnings?
PLIANT THERAPEUTICS, INC. (PLRX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001746473-26-000088). This is PLIANT THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is PLIANT THERAPEUTICS, INC.'s most recent earnings 8-K?
PLIANT THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001746473-26-000088. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PLIANT THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →